Compare Crispr Therapeutics AG (CRSP) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Northrop Grumman Corporation — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Northrop Grumman Corporation trades at $480.72 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 14.1× Crispr Therapeutics AG's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Northrop Grumman Corporation for 81 Days on average.
| CRSP | NOC | |
|---|---|---|
Market Cap | $4.88B | $68.83B |
Volume | 2,861,747 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $74.92 | $768.02 |
52-Week Low | $44.34 | $473.46 |
Typical Hold Time | 77 Days | 81 Days |
Enterprise Value | $3.30B | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.39, up 1.99% on the day, but remains in a bearish technical trend. The company shows no revenue in 2025, with significant losses (net income margin -4,101.26%) and negative cash flow from operations. However, analyst sentiment is positive with a 57.9% buy rating and a $67.83 consensus price target, citing upcoming clinical data catalysts for its gene-editing therapies like CASGEVY and zugo-cel.
The outlook hinges on successful clinical execution and commercialization of its pipeline. Near-term catalysts include data readouts in autoimmune diseases, but high cash burn, intense competition, and regulatory risks pose substantial challenges. The stock offers high-risk, high-reward potential for investors betting on gene-editing breakthroughs.
Northrop Grumman (NOC) trades at $480.72, up 1.53% on the day, with a bearish technical signal from moving averages but strong fundamentals including a P/E of 15.4 and ROE of 26.96%. Recent quarterly EPS beats and a consensus analyst price target of $600.62 suggest upside potential, though the stock faces headwinds from Boeing's recent $20 billion Navy fighter contract win (Seeking Alpha, 2026-10-02).
The outlook for NOC is supported by a record backlog and defense budget tailwinds, but competitive pressures and execution risks on key programs like the B-21 bomber pose challenges. Analyst sentiment is predominantly bullish with 54% buy ratings, indicating confidence in long-term growth despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
